Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner, Björn Hackanson, Michael Lübbert, et al.
Clinical Epigenetics (2010) Vol. 1, Iss. 3-4, pp. 117-136
Open Access | Times Cited: 385

Showing 1-25 of 385 citing articles:

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 589
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate
Peter J. Watson, Louise Fairall, Guilherme Santos, et al.
Nature (2012) Vol. 481, Iss. 7381, pp. 335-340
Open Access | Times Cited: 455
Modulators of Protein–Protein Interactions
L.‐G. Milroy, Tom N. Grossmann, Sven Hennig, et al.
Chemical Reviews (2014) Vol. 114, Iss. 9, pp. 4695-4748
Open Access | Times Cited: 454
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
Geneviève P. Delcuve, Dilshad H. Khan, James Davie
Clinical Epigenetics (2012) Vol. 4, Iss. 1
Open Access | Times Cited: 445
Chromatin proteins and modifications as drug targets
Kristian Helin, Dashyant Dhanak
Nature (2013) Vol. 502, Iss. 7472, pp. 480-488
Closed Access | Times Cited: 401
The epigenetic effects of butyrate: potential therapeutic implications for clinical practice
Roberto Berni Canani, Margherita Di Costanzo, Ludovica Leone
Clinical Epigenetics (2012) Vol. 4, Iss. 1
Open Access | Times Cited: 351
Small Changes Huge Impact: The Role of Protein Posttranslational Modifications in Cellular Homeostasis and Disease
Tejaswita M. Karve, Amrita K. Cheema
Journal of Amino Acids (2011) Vol. 2011, pp. 1-13
Open Access | Times Cited: 338
An overview of benzo [b] thiophene-based medicinal chemistry
Rangappa S. Keri, Karam Chand, Srinivasa Budagumpi, et al.
European Journal of Medicinal Chemistry (2017) Vol. 138, pp. 1002-1033
Closed Access | Times Cited: 284
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
Bas J. Wouters, Ruud Delwel
Blood (2015) Vol. 127, Iss. 1, pp. 42-52
Open Access | Times Cited: 262
Insights into the activation mechanism of class I HDAC complexes by inositol phosphates
Peter J. Watson, Christopher J. Millard, Andrew M. Riley, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 213
Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
Stefan H. E. Kaufmann, Christoph Lange, Martin Rao, et al.
The Lancet Respiratory Medicine (2014) Vol. 2, Iss. 4, pp. 301-320
Closed Access | Times Cited: 211
Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?
Ian F. Harrison, David T. Dexter
Pharmacology & Therapeutics (2013) Vol. 140, Iss. 1, pp. 34-52
Closed Access | Times Cited: 210
Zinc binding groups for histone deacetylase inhibitors
Lei Zhang, Jian Zhang, Qixiao Jiang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2018) Vol. 33, Iss. 1, pp. 714-721
Open Access | Times Cited: 194
HDAC Inhibitors in Acute Myeloid Leukemia
Edurne San José‐Eneriz, Naroa Gimenez-Camino, Xabier Agirre, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1794-1794
Open Access | Times Cited: 171
Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth
Joel Bergman, Karrune Woan, Patricio Perez-Villarroel, et al.
Journal of Medicinal Chemistry (2012) Vol. 55, Iss. 22, pp. 9891-9899
Open Access | Times Cited: 181
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
Blaž Grošelj, Nitin Sharma, Freddie C. Hamdy, et al.
British Journal of Cancer (2013) Vol. 108, Iss. 4, pp. 748-754
Open Access | Times Cited: 177
Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts That Supports Cancer Progression
Ermira Pazolli, Elise Alspach, Agnieszka Milczarek, et al.
Cancer Research (2012) Vol. 72, Iss. 9, pp. 2251-2261
Open Access | Times Cited: 176
Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives
Giuseppe Giannini, Walter Cabri, Caterina Fattorusso, et al.
Future Medicinal Chemistry (2012) Vol. 4, Iss. 11, pp. 1439-1460
Closed Access | Times Cited: 163
Targeting Class I Histone Deacetylases in a “Complex” Environment
Christopher J. Millard, Peter J. Watson, Louise Fairall, et al.
Trends in Pharmacological Sciences (2017) Vol. 38, Iss. 4, pp. 363-377
Closed Access | Times Cited: 159
Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
Zhiming Li, Wei‐Guo Zhu
International Journal of Biological Sciences (2014) Vol. 10, Iss. 7, pp. 757-770
Open Access | Times Cited: 146
Role of Epigenetics in Inflammation-Associated Diseases
Muthu K. Shanmugam, Gautam Sethi
Sub-cellular biochemistry/Subcellular biochemistry (2012), pp. 627-657
Closed Access | Times Cited: 134
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Gerard L. Brien, Daria G. Valerio, Scott A. Armstrong
Cancer Cell (2016) Vol. 29, Iss. 4, pp. 464-476
Open Access | Times Cited: 132
HDAC Inhibitors
Carine Robert, Feyruz V. Rassool
Advances in cancer research (2012), pp. 87-129
Closed Access | Times Cited: 129
Turning Off AKT: PHLPP as a Drug Target
Alexandra C. Newton, Lloyd C. Trotman
The Annual Review of Pharmacology and Toxicology (2014) Vol. 54, Iss. 1, pp. 537-558
Open Access | Times Cited: 122
Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo
Julia M. Gajer, Silviya D. Furdas, Albert Gründer, et al.
Oncogenesis (2015) Vol. 4, Iss. 2, pp. e137-e137
Open Access | Times Cited: 115
Page 1 - Next Page

Scroll to top